These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 11467310)

  • 1. Repaglinide dose response? A clinician's viewpoint.
    Strange P; Goldberg RB
    Diabetes Technol Ther; 2000; 2(1):119-21. PubMed ID: 11467310
    [No Abstract]   [Full Text] [Related]  

  • 2. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
    Rosak C; Hofmann U; Paulwitz O
    Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
    Ambavane V; Patil R; Ainapure SS
    J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213
    [No Abstract]   [Full Text] [Related]  

  • 4. Repaglinide dose response? A clinician's viewpoint.
    Schade DS
    Diabetes Technol Ther; 1999; 1(3):257-8. PubMed ID: 11475270
    [No Abstract]   [Full Text] [Related]  

  • 5. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients].
    Landgraf R
    MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Repaglinide for type 2 diabetes mellitus.
    Med Lett Drugs Ther; 1998 May; 40(1027):55-6. PubMed ID: 9618664
    [No Abstract]   [Full Text] [Related]  

  • 7. Enhancement of early- and late-phase insulin secretion and insulin sensitivity by the combination of repaglinide and metformin in type 2 diabetes mellitus.
    Rudovich NN; Leyck Dieken MG; Rochlitz H; Pfeiffer AF
    Exp Clin Endocrinol Diabetes; 2004 Jul; 112(7):395-400. PubMed ID: 15239026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comments on type 2 diabetes screening and treatment.
    Kolaczynski JW
    Am Fam Physician; 2000 Jan; 61(1):49-50. PubMed ID: 10643950
    [No Abstract]   [Full Text] [Related]  

  • 9. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes.
    Raskin P
    Diabetes Obes Metab; 2008 Dec; 10(12):1167-77. PubMed ID: 18494804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients.
    Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR
    Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency.
    Østergård T; Degn KB; Gall MA; Carr RD; Veldhuis JD; Thomsen MK; Rizza RA; Schmitz O
    J Clin Endocrinol Metab; 2004 Jan; 89(1):297-302. PubMed ID: 14715864
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of repaglinide addition to NPH insulin monotherapy on glycemic control in patients with type 2 diabetes.
    de Luis DA; Aller R; Cuellar L; Terroba C; Ovalle H; Izaola O; Romero E
    Diabetes Care; 2001 Oct; 24(10):1844-5. PubMed ID: 11574456
    [No Abstract]   [Full Text] [Related]  

  • 14. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study.
    Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ
    J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repaglinide-loaded long-circulating biodegradable nanoparticles: rational approach for the management of type 2 diabetes mellitus.
    Jain S; Saraf S
    J Diabetes; 2009 Mar; 1(1):29-35. PubMed ID: 20923517
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
    Owens D
    J Assoc Physicians India; 2001 Jan; 49 Spec No():54-61. PubMed ID: 11235607
    [No Abstract]   [Full Text] [Related]  

  • 17. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan.
    Bakiner O; Ertorer ME; Bozkirli E; Tutuncu NB; Demirag NG
    Acta Diabetol; 2009 Mar; 46(1):63-5. PubMed ID: 18825302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
    Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
    Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
    [TBL] [Abstract][Full Text] [Related]  

  • 19. For diabetes: a preprandial pill ..
    Health News; 1998 Jul; 4(9):5. PubMed ID: 9693447
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacokinetics, pharmacodynamics, and dose-response relationship of repaglinide in type 2 diabetes.
    Strange P; Schwartz SL; Graf RJ; Polvino W; Weston I; Marbury TC; Huang WC; Goldberg RB
    Diabetes Technol Ther; 1999; 1(3):247-56. PubMed ID: 11475269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.